Arabic Arabic English English French French German German
dark

Medidata, Labcorp Partner to Expand Decentralized Clinical Trials for Digital Biomarker Discovery

Medidata, Labcorp Partner to Expand Decentralized Clinical Trials for Digital Biomarker Discovery

What You Should Know:

– Medidata, a Dassault Systèmes company, today announced a first-of-its-kind partnership with Labcorp using the Medidata Sensor Cloud to introduce a new model to advance the use of medical-grade sensors in clinical trials and accelerate biomarker discovery.

– As part of the partnership, Medidata will receive and process medical-grade sensor data within drug, vaccine and device trials across Labcorp Drug Development’s clinical trial portfolio, enhancing their decentralized clinical trial (DCT) offerings.

– Using Medidata Sensor Cloud, Labcorp will enhance its decentralized clinical trial offerings through the collection and processing of medical-grade sensor data within drug, vaccine and device trials in an effort to accelerate and improve patient outcomes. In addition, Labcorp and Medidata will co-develop digital biomarkers across a broad array of medical devices and therapeutic areas. The goal of this is to build a library of digital biomarkers that can be used to advance therapeutic research and create new, digital diagnostics.

Medidata Sensor Cloud Background

Sensor Cloud is a transformative platform for managing a broad range of sensor and digital health technology data and establishing interoperability with other clinical data sources. Launched earlier this year, Sensor Cloud integrates seamlessly with the Medidata Clinical Cloud and supports remote, continuous patient data collection from both Medidata and third-party, medical-grade sensors. This innovation provides a more comprehensive view of the patient experience through cutting-edge data ingestion, data standardization across all sensor types, and deep analytical capabilities that will ultimately lead to new digital biomarker discovery and digital endpoint deployment.

In addition, Labcorp and Medidata will use Sensor Cloud to co-develop digital biomarkers across a broad array of medical devices and therapeutic areas. The goal of this first-of-its-kind collaboration is to build a library of digital biomarkers that can be used to advance therapeutic research and create new, digital diagnostics. The first project will be an at-home version of the Six Minute Walk Test (6MWT), which is widely used in clinics to measure functional capacity in patients with heart failure, pulmonary conditions, physical function disorders and rare diseases.

“Sensor Cloud solves key technical, operational, and analytical challenges that have historically stifled the widespread usage of medical devices in clinical research,” said Ben Schlatka, vice president of digital biomarker solutions at Medidata. “This technology is urgently needed, with device usage dramatically escalating as patients, sponsors and sites demand greater flexibility during clinical trials. Combining the power of Sensor Cloud with Labcorp’s innovative approach to clinical research and its scale in clinical diagnostics will transform how patient data are collected, managed, analyzed and leveraged—driving faster, more effective drug development and overall better health outcomes.”

Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Ginger Adds Spanish to On-Demand Mental Healthcare Offering

Next Post

COVID-19 update 14 September 2021

Related Posts
Total
0
Share